Price Disclosure Reductions for 2020 April Cycle

Page last updated: 1 October 2020

This summary only includes medicines taking a price disclosure reduction on 1 April 2020. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

The Department is continuing to implement statutory pricing functions, including price disclosure reductions for the current and future cycles. Any queries or concerns should be sent to pricedisclosure@health.gov.au.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2020 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2020.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2019 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2019 will also take the reduction on 1 April 2020 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 23 December 2019.

Indicative prices for 1 April 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2020. Subscribe to PBS News to receive notice when they become available.

Final prices for 1 Apr il 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2020.

It remains open for responsible persons to request a price increase. Further information about price increases can be found on the page Requesting a change to an existing price.

Excel version of 2020 April Cycle Outcomes Summary

2020 April Cycle Outcomes Summary
Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)	Legal Instrument MoA	Legal Instrument Form	Average AEMP ($)	WAPD (%) across a drug/MoA	WADP - potential April '20 PBS Price (AEMP) ($) per pharmaceutical item	October '19 AEMP ($)	Percentage difference between October '19 and April '20 PBS prices (AEMP) (%) per pharmaceutical item	Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item No originator brand determined Does not meet 30 month clock	Applicable Unadjusted Price Reduction 10% or 30%
abacavir with lamivudine	Oral	Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg	290.55	14.29%	249.03	290.55	14.29%	Does not meet 30 month clock	10
abacavir with lamivudine	Oral	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	290.55	14.29%	249.03	290.55	14.29%	Does not meet 30 month clock	10
acarbose	Oral	Tablet 100 mg	25.69	14.50%	21.96	25.69	14.52%	OWAPD	10
acarbose	Oral	Tablet 50 mg	18.14	14.50%	15.51	18.14	14.50%	OWAPD	10
aripiprazole	Oral	Tablet 10 mg	74.47	13.33%	64.54	74.47	13.33%	Does not meet 30 month clock	10
aripiprazole	Oral	Tablet 15 mg	105.68	13.33%	91.59	105.68	13.33%	Does not meet 30 month clock	10
aripiprazole	Oral	Tablet 20 mg	128.64	13.33%	111.49	128.64	13.33%	Does not meet 30 month clock	10
aripiprazole	Oral	Tablet 30 mg	156.76	13.33%	135.86	156.76	13.33%	Does not meet 30 month clock	10
atazanavir	Oral	Capsule 150 mg (as sulfate)	334.67	10.23%	300.43	334.67	10.23%	Does not meet 30 month clock	10
atazanavir	Oral	Capsule 200 mg (as sulfate)	446.24	10.23%	400.59	446.24	10.23%	Does not meet 30 month clock	10
atazanavir	Oral	Capsule 300 mg (as sulfate)	334.67	10.23%	300.43	334.67	10.23%	Does not meet 30 month clock	10
atomoxetine	Oral	Capsule 10 mg (as hydrochloride)	41.65	13.17%	36.16	41.65	13.18%	GWAPD	10
atomoxetine	Oral	Capsule 100 mg (as hydrochloride)	54.14	13.17%	47.01	54.14	13.17%	GWAPD	10
atomoxetine	Oral	Capsule 18 mg (as hydrochloride)	41.65	13.17%	36.16	41.65	13.18%	GWAPD	10
atomoxetine	Oral	Capsule 25 mg (as hydrochloride)	41.65	13.17%	36.16	41.65	13.18%	GWAPD	10
atomoxetine	Oral	Capsule 40 mg (as hydrochloride)	41.65	13.17%	36.16	41.65	13.18%	GWAPD	10
atomoxetine	Oral	Capsule 60 mg (as hydrochloride)	41.65	13.17%	36.16	41.65	13.18%	GWAPD	10
atomoxetine	Oral	Capsule 80 mg (as hydrochloride)	54.14	13.17%	47.01	54.14	13.17%	GWAPD	10
azacitidine	Injection	Powder for injection 100 mg	217.64	16.60%	181.51	217.64	16.60%	GWAPD	10
dexamethasone	Injection	Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL	5.69	38.39%	3.51	5.69	38.31%	No originator brand determined	30
dexamethasone	Injection	Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL	13.96	38.39%	8.60	13.96	38.40%	No originator brand determined	30
entecavir	Oral	Tablet 0.5 mg (as monohydrate)	168.85	28.19%	121.25	144.49	16.08%	Does not meet 30 month clock	10
entecavir	Oral	Tablet 1 mg (as monohydrate)	274.59	28.19%	197.18	234.98	16.09%	Does not meet 30 month clock	10
eplerenone	Oral	Tablet 25 mg	63.79	24.89%	47.91	63.79	24.89%	GWAPD	10
eplerenone	Oral	Tablet 50 mg	63.79	24.89%	47.91	63.79	24.89%	GWAPD	10
ezetimibe	Oral	Tablet 10 mg	29.44	40.34%	17.56	20.86	15.82%	Does not meet 30 month clock	10
ganciclovir	Injection	Powder for I.V. infusion 500 mg (as sodium)	200.67	21.08%	158.37	200.67	21.08%	Does not meet 30 month clock	10
imatinib	Oral	Capsule 100 mg (as mesilate)	851.25	51.11%	416.18	666.44	37.55%	GWAPD	10
imatinib	Oral	Capsule 400 mg (as mesilate)	1702.50	51.11%	832.35	1332.89	37.55%	GWAPD	10
imatinib	Oral	Tablet 100 mg (as mesilate)	851.25	51.11%	416.18	666.44	37.55%	GWAPD	10
imatinib	Oral	Tablet 400 mg (as mesilate)	1702.50	51.11%	832.35	1332.89	37.55%	GWAPD	10
lincomycin	Injection	Injection 600 mg (as hydrochloride monohydrate) in 2 mL	102.94	22.50%	79.78	92.49	13.74%	Does not meet 30 month clock	10
moxonidine	Oral	Tablet 200 micrograms	8.06	11.94%	7.10	8.06	11.91%	Does not meet 30 month clock	10
moxonidine	Oral	Tablet 400 micrograms	13.74	11.94%	12.10	13.74	11.94%	Does not meet 30 month clock	10
naloxone	Injection	Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe	34.36	19.17%	27.77	34.36	19.18%	Does not meet 30 month clock	10
naloxone	Injection	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	38.96	19.17%	31.49	38.96	19.17%	Does not meet 30 month clock	10
olmesartan	Oral	Tablet containing olmesartan medoxomil 20 mg	4.34	11.74%	3.83	4.34	11.75%	Does not meet 30 month clock	10
olmesartan	Oral	Tablet containing olmesartan medoxomil 40 mg	9.21	11.74%	8.13	9.21	11.73%	Does not meet 30 month clock	10
rizatriptan	Oral	Tablet (orally disintegrating) 10 mg (as benzoate)	4.57	10.44%	4.09	4.57	10.50%	GWAPD	10
rizatriptan	Oral	Wafer 10 mg (as benzoate)	4.57	10.44%	4.09	4.57	10.50%	GWAPD	10
rosuvastatin	Oral	Tablet 20 mg (as calcium)	7.31	30.04%	5.11	7.31	30.10%	GWAPD	30
rosuvastatin	Oral	Tablet 40 mg (as calcium)	10.43	30.04%	7.30	10.43	30.01%	GWAPD	30
rosuvastatin	Oral	Tablet 5 mg (as calcium)	3.50	30.04%	2.45	3.50	30.00%	GWAPD	30
tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	143.62	35.60%	92.49	143.62	35.60%	Does not meet 30 month clock	10
tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	143.62	35.60%	92.49	143.62	35.60%	Does not meet 30 month clock	10
tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg	143.62	35.60%	92.49	143.62	35.60%	Does not meet 30 month clock	10
tobramycin	Inhalation	Solution for inhalation 300 mg in 5 mL	938.45	25.30%	701.02	938.45	25.30%	GWAPD	10
valganciclovir	Oral	Tablet 450 mg (as hydrochloride)	1040.88	31.45%	713.52	902.27	20.92%	Does not meet 30 month clock	10
voriconazole	Oral	Tablet 200 mg	957.50	24.10%	726.74	957.50	24.10%	GWAPD	10
voriconazole	Oral	Tablet 50 mg	239.38	24.10%	181.69	239.38	24.10%	GWAPD	10
zoledronic acid	Injection	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL	173.89	32.14%	118.00	132.37	10.86%	GWAPD	10
zoledronic acid	Injection	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL vial	197.50	32.14%	134.02	197.50	32.14%	GWAPD	10
zoledronic acid	Injection	Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL	173.89	32.14%	118.00	132.37	10.86%	GWAPD	10
zoledronic acid	Injection	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	232.81	32.14%	157.98	177.21	10.85%	GWAPD	10

Price Disclosure Reductions for 2020 April Cycle

Flow-on Reductions for F2 Combination Items

Legal Determination & Next Steps

Department of Health and Aged Care

Pharmaceutical Benefits Scheme

PBS Information

Browse the PBS

For Health Professionals

For Industry